OncoSec Appoints Daniel J. O’Connor to its Board of Directors

OncoSec Medical Inc., known as “OncoSec” (NASDAQ: ONCS), which develops DNA-based intratumoral cancer immunotherapies, today announced the appointment of Daniel J. O’Connor to its board of directors.

O’Connor most recently served as president and CEO of Advaxis Immunotherapies, raising more than $250 million in funding.  Previously, he was senior vice president for ImClone Systems. O’Connor also served as general counsel at PharmaNet (Inventive Health) and was part of the senior leadership team that grew the company from a startup contract research organization into a leader in clinical research. O’Connor is a 1995 graduate of Penn State University’s Dickinson School of Law in Carlisle, PA, and he currently serves as an advisor to its dean.

“Dan is a proven leader with a strong track record of success. He brings exceptional strategic and operational expertise in building thriving, successful biopharma companies, and we are pleased to welcome Dan to the Board,” said Punit Dhillon, President and CEO of OncoSec. “His history with commercializing and licensing cancer immunotherapy products will be vital as we continue to progress our lead melanoma program through clinical trials and registration.”